S06-2 From the Aspect of Drug Information

◯Yasufumi SAWADA[1]

[1]Graduate School of Pharmaceutical Sciences

A drug can be used as a pharmaceutical product only when accompanied with relevant information. The information provided at the time of market introduction is often the minimum required, and not always sufficient. While a drug product placed on the market is unchanged until the development of a new dosage form, drug information is updated on a daily basis, and outdated information is discarded. For post-marketing proper drug use and drug evolution, on the other hand, drug information is provided and delivered to the clinical setting in a new useful form after drug information materials are collected, evaluated, analyzed, reconstructed, standardized, and digitized. In addition, drug information is fed back to pharmaceutical companies to serve as a basis for better drug discovery. In the drug informatics involved, researchers are committed to generating new drug information contents and developing platforms for information loading and infrastructure for information provision and delivery. Any problem with drug information contents, platforms, and/or infrastructure layers may result in an increased risk of improper drug use and medical errors on the side of consumers and medical personnel. Therefore, risk management is always necessary in this field as well. In this talk, we would like to introduce our efforts aimed at promoting risk management and enhancing the quality of drug information contents and dissemination.